It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Although the first-line therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma is the eradication of Helicobacter pylori, the effect of eradication in Helicobacter pylori-negative cases is unclear. In this case report, we describe a surgical option for a case of Barrett’s esophageal cancer with concurrent gastric mucosa-associated lymphoid tissue lymphoma.
Case presentation
A 79-year-old man was admitted to our hospital with Barrett’s esophageal cancer and gastric mucosa-associated lymphoid tissue lymphoma. Initially, we performed endoscopic submucosal dissection for Barrett’s esophageal cancer. Since residual tumor was observed after the endoscopic submucosal dissection, we performed an esophagectomy with two-field lymph node dissection, which was followed by placement of a gastric conduit via the posterior mediastinal route. He was discharged 14 days after surgery. Although no additional treatment exists for mucosa-associated lymphoid tissue lymphoma, no recurrent disease has been detected to date.
Conclusion
An option to use a portion of the stomach with low-grade malignant mucosa-associated lymphoid tissue lymphoma as a conduit after esophagectomy was suggested.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Chiba Cancer Center, Division of Gastroenterological Surgery, Chiba, Japan (GRID:grid.418490.0) (ISNI:0000 0004 1764 921X); Toho University, Department of Surgery, Toho University Medical Center, Omori Hospital, Graduate School of Medicine, Tokyo, Japan (GRID:grid.265050.4) (ISNI:0000 0000 9290 9879)
2 Chiba Cancer Center, Division of Gastroenterological Surgery, Chiba, Japan (GRID:grid.418490.0) (ISNI:0000 0004 1764 921X)
3 Toho University, Department of Surgery, Toho University Medical Center, Omori Hospital, Graduate School of Medicine, Tokyo, Japan (GRID:grid.265050.4) (ISNI:0000 0000 9290 9879); Toho University Graduate School of Medicine, Department of Clinical Oncology, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)